Eli Lilly on Thursday said its daily obesity pill met the company’s goals in the first of several late-stage trials, helping patients with Type 2 diabetes lower their blood sugar and body weight and showing safety comparable with popular injections on the market. The trial results are among the pharmaceutical industry’s most closely watched studies…
The Lilly Biotechnology Center in San Diego, California, on March 1, 2023. Mike Blake | Reuters Shares of drugmakers fell on Wednesday after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. Shares of U.S.-based companies Eli Lilly, AbbVie, Bristol Myers Squibb and Regeneron all fell about 4%…
Check out the companies making headlines before the bell. Pharmaceutical stocks – Shares of U.S. companies in the pharmaceutical industry fell after President Donald Trump said late Tuesday that he’s going to announce ” very shortly a major tariff on pharmaceuticals .” Pfizer and Merck shares each dropped more than 4%, while Eli Lilly shed…
Check out the companies making headlines in midday trading: Tech stocks — Shares of megacap technology names fell after initially gaining amid investor optimism that the U.S. would reach deals with other countries to lower tariffs. Apple , which lost around 20% over the past three trading days given its China exposure, finished about 5%…
Check out the companies making headlines before the bell: Levi Strauss — The jeans maker surged 11% after the company reiterated its full-year outlook. However, Levi noted that it excludes any impact from the White House’s tariffs. The company also posted first-quarter adjusted earnings of 38 cents per share, which was 52% higher versus the…
The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020. Mike Blake | Reuters Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration’s ban on the practice and luring people away from Lilly’s…
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four…
This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly‘s weight-loss drug Zepbound and its diabetes drug Mounjaro. Online, it doesn’t look like much has changed. Popular websites like Amble, EllieMD, Willow and Mochi Health are all still advertising versions of tirzepatide, the active ingredient in Zepbound. Some,…
Check out the companies making headlines in premarket trading: Nvidia — Shares of the chipmaker rebounded about 2% on Wednesday morning, regaining some lost ground from this week. The stock is down more than 7% so far week to date. CrowdStrike — The cybersecurity firm pulled back more than 7%. CrowdStrike sees full-year revenue in…
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market. “We’re delighted to share…
